Acute Leukemia Articles & Analysis: This-Year
3 articles found
A major breakthrough occurred with the FDA approval of Venetoclax (ABT-199), a BCL2-selective inhibitor used in the treatment of chronic lymphocytic leukemia (CLL). Venetoclax works by mimicking BH3-only proteins, thereby displacing pro-survival BCL2 proteins and triggering apoptosis in cancer cells. In 2020, a study published in the New England Journal of Medicine demonstrated ...
This immunotherapy has shown remarkable success, particularly in hematologic malignancies such as acute lymphoblastic leukemia and certain types of lymphoma. However, the complexity and high costs associated with CAR-T development have prompted researchers and companies to seek more efficient and effective approaches. ...
Immunotherapy in Leukemia Treatment Immunotherapy represents a paradigm shift in the treatment of leukemia. ...